The Osteogenesis Imperfecta Treatment Market Is Estimated To...

The Osteogenesis Imperfecta Treatment Market Is Estimated To Witness High Growth Owing To Increasing Research And Development Of Novel Therapies

Posted 2024-01-29 12:17:47

957

Osteogenesis imperfecta, commonly known as brittle bone disease, is a genetic disorder that causes bones to break easily, often from little to no apparent cause or minor injury. Those with the condition have mutations in their collagen that make their bones less dense, thinner, and more fragile. Current treatment options are aimed at relieving pain, preventing fractures, and improving mobility and may include physical therapy, orthopedic devices, braces, wheelchairs, and medications.

The global osteogenesis imperfecta treatment market is estimated to be valued at US$ 832.67 Mn in 2023 and is expected to exhibit a CAGR of 4.2% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.

Market Dynamics

One of the key drivers for the growth of the osteogenesis imperfecta treatment market is the increasing research and development of novel therapies. For instance, in October 2022, Astellas Pharma Inc and Bone Therapeutics announced positive topline results from the ongoing phase 2B BETTER study evaluating the investigational bone anabolic agent, ALLOB, in patients with osteogenesis imperfecta. The study demonstrated that patients receiving ALLOB 100 μg/kg showed statistically significant improvement from baseline in lumbar spine Bone Mineral Density as compared to the placebo group at 12 months. Such ongoing clinical trials evaluating novel treatments for osteogenesis imperfecta are expected to contribute significantly to the market growth over the forecast period. Additionally, increasing prevalence of osteogenesis imperfecta globally is also expected to fuel the demand for treatment options over the coming years. According to data by NORD, the rare diseases organization, osteogenesis imperfecta affects approximately 1 in 15,000 to 20,000 people worldwide.

SWOT Analysis

Strength: Osteogenesis Imperfecta Treatment has strong growth opportunities. Non-invasive genetic counseling and advance surgical techniques can help patients manage the disease better. Developing drugs to address the root cause of brittle bones shows promise.

Weakness: Lack of awareness about Osteogenesis Imperfecta remains a challenge. Limited treatment options make it difficult to completely cure the condition. High cost of specialized care poses barriers.

Opportunity: Rising healthcare spending in developing nations is expanding access to treatment. More research on gene and cell therapies can lead to groundbreaking solutions. Personalized management tailored to each patient's needs can boost outcomes.

Threats: Stringent regulations for new drugs may delay market approvals. Follow-on biologics face pricing competition once patents expire on flagship brands. Economic slowdowns can restrictive healthcare budgets.

Key Takeaways

The global Osteogenesis Imperfecta Treatment Market Share is expected to witness high growth. Being a rare genetic disorder, increasing diagnosis and dedicated research funding are positively impacting the market. The global Osteogenesis Imperfecta Treatment Market is estimated to be valued at US$ 832.67 Mn in 2023 and is expected to exhibit a CAGR of 4.2% over the forecast period 2024 to 2031.

Regional analysis related content comprises: North America currently dominates due to advanced healthcare facilities and widespread medical insurance. Asia Pacific is witnessing rapid expansion led by China, India with their growing medical tourism industries, increasing disposable incomes and large patient pools.

Key players related content comprises: Key players operating in the Osteogenesis Imperfecta Treatment market are AmSurg Corp., HCA Holdings, Inc., Tenet Healthcare, Surgical Care Affiliates, Inc., Surgery Partners, Ambulatory Surgical Centers of America, Heathway Medical Group, Community Health Systems, Inc., and Vision Group Holdings